AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Results of Operations and Financial Condition

AVEXIS,INC. (NASDAQ:AVXS) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial
Condition.

On May11, 2017, AveXis,Inc. (the Registrant)
issued a press release announcing the Registrants financial
results for the first quarter ended March31, 2017. A copy of this
press release is furnished herewith as Exhibit99.1 to this
Current Report on Form8-K and is incorporated herein by
reference.

The information in this Item 2.02 of this Current Report on
Form8-K (including Exhibit99.1) is being furnished and shall not
be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or
otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and
Exhibits.

(d)Exhibits

Exhibit

Number

ExhibitDescription

99.1

Press Release, dated May11, 2017, titled AveXis Reports
First Quarter 2017 Financial and Operating Results.


About AVEXIS, INC. (NASDAQ:AVXS)

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

AVEXIS, INC. (NASDAQ:AVXS) Recent Trading Information

AVEXIS, INC. (NASDAQ:AVXS) closed its last trading session down -0.78 at 76.46 with 164,477 shares trading hands.

An ad to help with our costs